What is ImmunoReagents?
ImmunoReagents, Inc. is a key manufacturer specializing in high-quality reagents essential for the pharmaceutical, biotechnology, life science research, and in vitro diagnostics industries. The company's comprehensive product portfolio includes a diverse array of primary and secondary antibodies, immunoassay reagents, and antibody purification tools. These offerings are meticulously optimized for critical applications such as ELISA, IHC, and Western blotting, demonstrating ImmunoReagents' commitment to advancing scientific discovery and diagnostic capabilities. Recognized for its role as a prominent OEM reagent antibody manufacturer, ImmunoReagents provides crucial components for diagnostic assays, positioning itself as a vital partner in the healthcare ecosystem.
How much funding has ImmunoReagents raised?
ImmunoReagents has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for ImmunoReagents?
The substantial late-stage funding indicates ImmunoReagents is poised for significant scaling and strategic development. This capital infusion is expected to fuel further innovation in reagent technology, expand manufacturing capacity, and potentially broaden market reach into new diagnostic and research areas. The company's focus on providing cost-effective, tailored solutions, coupled with its OEM capabilities, suggests a trajectory aimed at solidifying its leadership in the competitive life sciences market and supporting the development of next-generation diagnostics and therapeutics.
See full ImmunoReagents company page
